PLx Pharma Appoints CEO
This article was originally published in Scrip
PLx Pharma Inc. has appointed Natasha Giordano CEO replacing Ronald R. Zimmerman, who will remain on the company's board of directors and continue in his role as founder and senior advisor. Giordano has also been appointed president and member of the board and brings over 25 years' experience to the company. Before PLx, she was president and CEO of Clear Point Learning and prior to this she held the same positions at Healthcare Corporation of America. Previously, Giordano was also president and CEO of Xanodyne Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.